92
Participants
Start Date
June 30, 2008
Primary Completion Date
January 31, 2011
Study Completion Date
May 31, 2013
Endoxana, Leukine, IMA910
a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
Endoxana, Leukine, IMA910, Aldara
a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
Pauls Stradins University Hospital, Riga
State Health Center Oncology, Budapest
Péterfy Hospital, Budapest
Latvia oncological Center, Riga
Semmelweis University, Oncoradiology, Budapest
"National Institute of Oncology, Department of Internal Medicine, Department of Chemotherapy B", Budapest
Uszoki Hospital, Budapest
District Dispensary for Oncology Diseases with Inpatient Unit, Sofia District, Chemotherapeutic Ward, Sofia
"MHAT Tsaritsa Yoanna, Clinic of Oncotherapy", Sofia
Specialized Hospital for Active Treatment in Oncology Ltd., Clinic of Chemotherapy, Sofia
Medische Oncologie, Imeldaziekenhuis, Bonheiden
Borsod County Hospital, Miskolc
Inter District Dispencary for Oncology Disease with Inpatient Unit Plovdiv, First Internal Ward, Plovdiv
University of Szeged, Department of Oncotherapy, Szeged
St. Gyorgy County Hospital, Székesfehérvár
Oncologisch Centrum, UZ Gent, Ghent
"Interdistrict Dispensary of Oncology Diseases with Inpatient Unit Dr. Marko Markov - Varna", Varna
Institute for Oncology and Radiology of Serbia, National Cancer Research Center, Clinical Research and Exp. Pharmacology, Belgrade
Vojnomedicinska Akademija, Clinic for Gastroenterology, Military Medical Academy, Belgrade
Oncology Institute of Vojvodina, Sremska
Prosper-Hospital, Med. Klinik I, Recklinghausen
Krankenhaus Nordwest der Stiftung Hospital zum heiligen Geist, II. med. Klinik, Frankfurt a.M.
University of Tübingen, Department of med. Oncology, Hematology, Immunology, Rhematology and Pulmology, Tübingen
Kliniken Villingen, Schwarzwald-Baar-Klinik, Dept. Of Hematology & Oncology, Villingen-Schwenningen
Cancer Hospital Sanafontis, Freiburg im Breisgau
Wojewodzki Szpital Zespolony im. Ludwika Rydygiera, Oddzial Chemiotherapii, Torun
Universitätsklinikum Ulm, Dep. Of Internal Medicine I, Studiensekretariat, CCCU, CTOA, Ulm
"Oncology Institute Prof. Dr. Ion Chiricuta", Cluj-Napoca
Spitalul Clinic Judetean, Târgu Mureş
Clinical County Hospital Oradea, Oncology Clinic, Oradea
"University Hospital Dresden Carl Gustav Carus", Dresden
Centrum Onkologii Instytut im. Marii Skłodowskiej-Curie Klinika Onkologii Klinicznej, Gliwice
Klinika Chemioterapii Nowotworów, Regionalny Ośrodek Onkologiczny, Wojewódzki Szpital Specjalistyczny im. M.Kopernika Uniwersytetu Medycznego Łódz, Lodz
Katedra i Klinika Hematologii, Onkologii i Cherob Wewnetrznych AM SP Centralny Szpital Kliniczny w Warszawie, Warsaw
The Royal Sussex County Hospital, CIR-Unit, Brighton
University of Cambridge, Department of Oncology, Cambridge
Velindre Cancer Centre, Cardiff
St Luke's Cancer Centre, The Royal Surrey County Hospital, Guildford / Surrey
St. James's Hospital, Leeds
Leicester Royal Infirmary, Leicester
Churchill Hospital, Dept.of Clinical Pharmacology, Oxford
Lead Sponsor
Immatics Biotechnologies GmbH
INDUSTRY